This group has previously reported the results of a similar clinical trial using ex vivo-expanded allogeneic donor-derived CTL clones employing repetitive stimulation of the HLA-A*02:01-restricted WT1 epitope for treatment of relapsed or high-risk AML after allo-HSCT [69]. Here, HLA-A is linked to acute myeloid leukemia.